Eintrag weiter verarbeiten
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients
Gespeichert in:
| Zeitschriftentitel: | Artificial Organs |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Artificial Organs, 42, 2018, 2, S. 141-147 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur |
|---|---|
| author |
Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur |
| spellingShingle |
Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur Artificial Organs Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients Biomedical Engineering General Medicine Biomaterials Medicine (miscellaneous) Bioengineering |
| author_sort |
pac, mustafa |
| spelling |
Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur 0160-564X 1525-1594 Wiley Biomedical Engineering General Medicine Biomaterials Medicine (miscellaneous) Bioengineering http://dx.doi.org/10.1111/aor.12989 <jats:title>Abstract</jats:title><jats:p>The HeartWare HVAD is a small, third generation continuous flow pump that is intracorporeally placed for support of a failing ventricle in adult patients. This device is small in size when compared to other left ventricular assist devices and can therefore be used in smaller sized pediatric patients. We present our initial experience using the HVAD as a bridge to heart transplantation in the pediatric population. We performed a retrospective, single center, nonrandomized review of 17 pediatric patients who underwent HVAD implantation between June 2013 and March 2016. The primary endpoints evaluated in this study were overall survival to heart transplantation, ongoing device support, or death. In this patient cohort, nine (53%) of 17 patients were male. The median age of the patients was 13.4 ± 3.8 (range 5–17) years. The median body surface area was 1.4 ± 0.4(0.7–2) m<jats:sup>2</jats:sup>. Etiologies of heart failure requiring HVAD support were dilated cardiomyopathy (<jats:italic>n</jats:italic> = 8), myocarditis (<jats:italic>n</jats:italic> = 5) and noncompaction cardiomyopathy (<jats:italic>n</jats:italic> = 4). The overall mean length of HVAD support was 254 ± 298 (range 2–804) days. A successful outcome (bridge to transplant and ongoing mechanical support) was achieved in 13 patients (76.5%). Of the 13 patients, nine (69.2%) were bridged to heart transplantation and four continue to receive support (30.7%) and are eligible for transplantation. Post‐transplant survival has been 100%, with a mean follow‐up of 296 ± 264.5 (range 18–785) days. The most common complication was pump thrombosis (23.5%) in follow‐up. Four patients (23.5%) experienced no complications. The HVAD continuous flow ventricular assist device can be safely used to bridge pediatric patients to cardiac transplantation. Favorable outcomes of this device are comparable to the adult population. This analysis demonstrated safe and effective implantation of the HVAD System in a child with a BSA of 0.7 m<jats:sup>2</jats:sup>.</jats:p> Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients Artificial Organs |
| doi_str_mv |
10.1111/aor.12989 |
| facet_avail |
Online |
| finc_class_facet |
Biologie Medizin Technik Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hb3IuMTI5ODk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hb3IuMTI5ODk |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 |
| imprint |
Wiley, 2018 |
| imprint_str_mv |
Wiley, 2018 |
| issn |
0160-564X 1525-1594 |
| issn_str_mv |
0160-564X 1525-1594 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
pac2018thirdgenerationventricularassistdevicemidtermoutcomesoftheheartwarehvadinpediatricpatients |
| publishDateSort |
2018 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Artificial Organs |
| source_id |
49 |
| title |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_unstemmed |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_full |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_fullStr |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_full_unstemmed |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_short |
Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_sort |
third generation ventricular assist device: mid‐term outcomes of the heartware hvad in pediatric patients |
| topic |
Biomedical Engineering General Medicine Biomaterials Medicine (miscellaneous) Bioengineering |
| url |
http://dx.doi.org/10.1111/aor.12989 |
| publishDate |
2018 |
| physical |
141-147 |
| description |
<jats:title>Abstract</jats:title><jats:p>The HeartWare HVAD is a small, third generation continuous flow pump that is intracorporeally placed for support of a failing ventricle in adult patients. This device is small in size when compared to other left ventricular assist devices and can therefore be used in smaller sized pediatric patients. We present our initial experience using the HVAD as a bridge to heart transplantation in the pediatric population. We performed a retrospective, single center, nonrandomized review of 17 pediatric patients who underwent HVAD implantation between June 2013 and March 2016. The primary endpoints evaluated in this study were overall survival to heart transplantation, ongoing device support, or death. In this patient cohort, nine (53%) of 17 patients were male. The median age of the patients was 13.4 ± 3.8 (range 5–17) years. The median body surface area was 1.4 ± 0.4(0.7–2) m<jats:sup>2</jats:sup>. Etiologies of heart failure requiring HVAD support were dilated cardiomyopathy (<jats:italic>n</jats:italic> = 8), myocarditis (<jats:italic>n</jats:italic> = 5) and noncompaction cardiomyopathy (<jats:italic>n</jats:italic> = 4). The overall mean length of HVAD support was 254 ± 298 (range 2–804) days. A successful outcome (bridge to transplant and ongoing mechanical support) was achieved in 13 patients (76.5%). Of the 13 patients, nine (69.2%) were bridged to heart transplantation and four continue to receive support (30.7%) and are eligible for transplantation. Post‐transplant survival has been 100%, with a mean follow‐up of 296 ± 264.5 (range 18–785) days. The most common complication was pump thrombosis (23.5%) in follow‐up. Four patients (23.5%) experienced no complications. The HVAD continuous flow ventricular assist device can be safely used to bridge pediatric patients to cardiac transplantation. Favorable outcomes of this device are comparable to the adult population. This analysis demonstrated safe and effective implantation of the HVAD System in a child with a BSA of 0.7 m<jats:sup>2</jats:sup>.</jats:p> |
| container_issue |
2 |
| container_start_page |
141 |
| container_title |
Artificial Organs |
| container_volume |
42 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792344056086396932 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:01:29.906Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Third+Generation+Ventricular+Assist+Device%3A+Mid%E2%80%90Term+Outcomes+of+the+HeartWare+HVAD+in+Pediatric+Patients&rft.date=2018-02-01&genre=article&issn=1525-1594&volume=42&issue=2&spage=141&epage=147&pages=141-147&jtitle=Artificial+Organs&atitle=Third+Generation+Ventricular+Assist+Device%3A+Mid%E2%80%90Term+Outcomes+of+the+HeartWare+HVAD+in+Pediatric+Patients&aulast=Pac&aufirst=Feyza+Aysenur&rft_id=info%3Adoi%2F10.1111%2Faor.12989&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792344056086396932 |
| author | Pac, Mustafa, Kocabeyoglu, Sinan Sabit, Kervan, Umit, Sert, Dogan Emre, Koca, Serhat, Ece, Ibrahim, Pac, Feyza Aysenur |
| author_facet | Pac, Mustafa, Kocabeyoglu, Sinan Sabit, Kervan, Umit, Sert, Dogan Emre, Koca, Serhat, Ece, Ibrahim, Pac, Feyza Aysenur, Pac, Mustafa, Kocabeyoglu, Sinan Sabit, Kervan, Umit, Sert, Dogan Emre, Koca, Serhat, Ece, Ibrahim, Pac, Feyza Aysenur |
| author_sort | pac, mustafa |
| container_issue | 2 |
| container_start_page | 141 |
| container_title | Artificial Organs |
| container_volume | 42 |
| description | <jats:title>Abstract</jats:title><jats:p>The HeartWare HVAD is a small, third generation continuous flow pump that is intracorporeally placed for support of a failing ventricle in adult patients. This device is small in size when compared to other left ventricular assist devices and can therefore be used in smaller sized pediatric patients. We present our initial experience using the HVAD as a bridge to heart transplantation in the pediatric population. We performed a retrospective, single center, nonrandomized review of 17 pediatric patients who underwent HVAD implantation between June 2013 and March 2016. The primary endpoints evaluated in this study were overall survival to heart transplantation, ongoing device support, or death. In this patient cohort, nine (53%) of 17 patients were male. The median age of the patients was 13.4 ± 3.8 (range 5–17) years. The median body surface area was 1.4 ± 0.4(0.7–2) m<jats:sup>2</jats:sup>. Etiologies of heart failure requiring HVAD support were dilated cardiomyopathy (<jats:italic>n</jats:italic> = 8), myocarditis (<jats:italic>n</jats:italic> = 5) and noncompaction cardiomyopathy (<jats:italic>n</jats:italic> = 4). The overall mean length of HVAD support was 254 ± 298 (range 2–804) days. A successful outcome (bridge to transplant and ongoing mechanical support) was achieved in 13 patients (76.5%). Of the 13 patients, nine (69.2%) were bridged to heart transplantation and four continue to receive support (30.7%) and are eligible for transplantation. Post‐transplant survival has been 100%, with a mean follow‐up of 296 ± 264.5 (range 18–785) days. The most common complication was pump thrombosis (23.5%) in follow‐up. Four patients (23.5%) experienced no complications. The HVAD continuous flow ventricular assist device can be safely used to bridge pediatric patients to cardiac transplantation. Favorable outcomes of this device are comparable to the adult population. This analysis demonstrated safe and effective implantation of the HVAD System in a child with a BSA of 0.7 m<jats:sup>2</jats:sup>.</jats:p> |
| doi_str_mv | 10.1111/aor.12989 |
| facet_avail | Online |
| finc_class_facet | Biologie, Medizin, Technik, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9hb3IuMTI5ODk |
| imprint | Wiley, 2018 |
| imprint_str_mv | Wiley, 2018 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161 |
| issn | 0160-564X, 1525-1594 |
| issn_str_mv | 0160-564X, 1525-1594 |
| language | English |
| last_indexed | 2024-03-01T17:01:29.906Z |
| match_str | pac2018thirdgenerationventricularassistdevicemidtermoutcomesoftheheartwarehvadinpediatricpatients |
| mega_collection | Wiley (CrossRef) |
| physical | 141-147 |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Artificial Organs |
| source_id | 49 |
| spelling | Pac, Mustafa Kocabeyoglu, Sinan Sabit Kervan, Umit Sert, Dogan Emre Koca, Serhat Ece, Ibrahim Pac, Feyza Aysenur 0160-564X 1525-1594 Wiley Biomedical Engineering General Medicine Biomaterials Medicine (miscellaneous) Bioengineering http://dx.doi.org/10.1111/aor.12989 <jats:title>Abstract</jats:title><jats:p>The HeartWare HVAD is a small, third generation continuous flow pump that is intracorporeally placed for support of a failing ventricle in adult patients. This device is small in size when compared to other left ventricular assist devices and can therefore be used in smaller sized pediatric patients. We present our initial experience using the HVAD as a bridge to heart transplantation in the pediatric population. We performed a retrospective, single center, nonrandomized review of 17 pediatric patients who underwent HVAD implantation between June 2013 and March 2016. The primary endpoints evaluated in this study were overall survival to heart transplantation, ongoing device support, or death. In this patient cohort, nine (53%) of 17 patients were male. The median age of the patients was 13.4 ± 3.8 (range 5–17) years. The median body surface area was 1.4 ± 0.4(0.7–2) m<jats:sup>2</jats:sup>. Etiologies of heart failure requiring HVAD support were dilated cardiomyopathy (<jats:italic>n</jats:italic> = 8), myocarditis (<jats:italic>n</jats:italic> = 5) and noncompaction cardiomyopathy (<jats:italic>n</jats:italic> = 4). The overall mean length of HVAD support was 254 ± 298 (range 2–804) days. A successful outcome (bridge to transplant and ongoing mechanical support) was achieved in 13 patients (76.5%). Of the 13 patients, nine (69.2%) were bridged to heart transplantation and four continue to receive support (30.7%) and are eligible for transplantation. Post‐transplant survival has been 100%, with a mean follow‐up of 296 ± 264.5 (range 18–785) days. The most common complication was pump thrombosis (23.5%) in follow‐up. Four patients (23.5%) experienced no complications. The HVAD continuous flow ventricular assist device can be safely used to bridge pediatric patients to cardiac transplantation. Favorable outcomes of this device are comparable to the adult population. This analysis demonstrated safe and effective implantation of the HVAD System in a child with a BSA of 0.7 m<jats:sup>2</jats:sup>.</jats:p> Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients Artificial Organs |
| spellingShingle | Pac, Mustafa, Kocabeyoglu, Sinan Sabit, Kervan, Umit, Sert, Dogan Emre, Koca, Serhat, Ece, Ibrahim, Pac, Feyza Aysenur, Artificial Organs, Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients, Biomedical Engineering, General Medicine, Biomaterials, Medicine (miscellaneous), Bioengineering |
| title | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_full | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_fullStr | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_full_unstemmed | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_short | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| title_sort | third generation ventricular assist device: mid‐term outcomes of the heartware hvad in pediatric patients |
| title_unstemmed | Third Generation Ventricular Assist Device: Mid‐Term Outcomes of the HeartWare HVAD in Pediatric Patients |
| topic | Biomedical Engineering, General Medicine, Biomaterials, Medicine (miscellaneous), Bioengineering |
| url | http://dx.doi.org/10.1111/aor.12989 |